Targeting synthetic lethality between the SRC kinase and the EPHB6 receptor may benefit cancer treatment.
Paul JM, Toosi B, Vizeacoumar FS, Bhanumathy KK, Li Y, Gerger C, El Zawily A, Freywald T, Anderson DH, Mousseau D, Kanthan R, Zhang Z, Vizeacoumar FJ, Freywald A.
Paul JM, et al. Among authors: li y.
Oncotarget. 2016 Aug 2;7(31):50027-50042. doi: 10.18632/oncotarget.10569.
Oncotarget. 2016.
PMID: 27418135
Free PMC article.